Desmopressin Acetate 0.2 mg Tablets, Fasting

NCT ID: NCT00835211

Last Updated: 2009-09-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-07-31
• Study Completion Date: 2003-08-31

Brief Summary

The objective of this study was to compare the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

Desmopressin Acetate 0.2 mg Tablets

Intervention Type: DRUG

4 x 0.2 mg, single-dose fasting

2

Group Type: ACTIVE_COMPARATOR

DDAVP® 0.2 mg Tablets

Intervention Type: DRUG

4 x 0.2 mg, single-dose fasting

Interventions

Desmopressin Acetate 0.2 mg Tablets

4 x 0.2 mg, single-dose fasting

Intervention Type: DRUG

DDAVP® 0.2 mg Tablets

4 x 0.2 mg, single-dose fasting

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy adult non-smoker (for at least 3 months) or light smoking (less than 10 cigarettes per day for at least 3 months) male or female subjects, 18-55 years of age;
• Weighing at least 60 kg for males and 52 kg for females;
• Subjects who had a body mass index (BMI) less than 30;
• Medically healthy subjects with clinically normal laboratory profiles and ECGs;

Females of childbearing potential should have either been sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or have been using one of the following acceptable birth control methods:

• surgically sterile (tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum. Proof was required for the hysterectomy and oophorectomy;
• IUD in place for at least 3 months;
• barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose and throughout the study;
• surgical sterilization of the partner (vasectomy for 6 months minimum);
• hormonal contraceptives for at least 3 months prior to the first dose of the study.

Other birth control methods were deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years were eligible.

• Voluntarily consent to participate in the study.

Exclusion Criteria

• Female subjects who were pregnant or lactating.
• Subjects who had been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study.
• Any clinically significant illness within 4 weeks prior to dosing.
• Subjects with any medical condition requiring regular treatment with prescription drugs.
• The use of any pharmacological agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose.
• Subjects who, through completion of the study, would have donated in excess of: 500 mL of blood and/or plasma in 14 days; 1500 mL of blood and/or plasma in 180 days; 2500 mL of blood and/or plasma in 1 year.
• Subjects who had donated plasma within 30 days prior to the first dose.
• Subjects who ahd participated in another clinical trial within 30 days prior to the first dose.
• Subjects who did not tolerate venipuncture.
• History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.

In addition, the history or presence of:

• hypersensitivity or idiosyncratic reaction to desmopressin or any other synthetic anti-diuretic hormones;
• type IIB von Willebrand's disease;
• personal or family bleeding disorder;
• alcoholism or drug abuse within the past year.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Principal Investigators

Gaetano Morelli, M.D.

Role: PRINCIPAL_INVESTIGATOR

MDS Pharma Services

Locations

MDS Pharma Sercives

Saint-Laurent, Quebec, Canada

Countries

Canada

Other Identifiers

AA04887

Identifier Type: -

Identifier Source: org_study_id